real-time news and commentary for investors
Thursday, Apr 18
Inovio Pharmaceuticals (INO +0.4%) says Phase 1 studies of its SynCon universal H1N1 influenza...
Inovio Pharmaceuticals (INO +0.4%) says Phase 1 studies of its SynCon universal H1N1 influenza vaccine generated protective antibody levels comparable to a current FDA-approved seasonal influenza vaccine against a currently circulating influenza strain. INO adds that this is the first demonstration of a SynCon influenza vaccine achieving a protective immune response rate comparable to a conventional seasonal vaccine for a circulating influenza strain.